Background and Purpose-Accumulating evidence suggests that telomere length is a maker for biological aging of the cardiovascular system. Whether stroke is associated with accelerated biological aging as measured by telomere length has not been conclusively demonstrated. Our aim was to determine whether mean leukocyte telomere length is a predictor for the development of stroke. Methods-The relative telomere length of leukocytes was determined by quantitative polymerase chain reaction in 1309 stroke patients and 1309 age-and sex-matched control subjects as well as 858 stroke patients followed prospectively for 5 years. For each measure, the study sample was divided into quartiles. The associations between the telomere length and risk of stroke as well as poststroke adverse outcomes were determined. Results-Mean telomere length was significantly shorter in stroke patients than in control subjects. Shorter telomere length levels were directly associated with a higher risk of stroke in the case/control sample. As compared with the fourth (longest) quartile, the odd ratios [OR] (and 95% confidence intervals [CI]) for ischemic stroke risk were as follows: third quartile, 1.37 (1.04 -1.82); second quartile, 1.53 (1.17-2.02); and first quartile, 2.12 (1.62-2.77). Follow-up of the patients from the prospective cohort also showed that shorter telomere length levels were associated with mortality from all causes but not with recurrence of stroke. Conclusions-Shorter telomere length was associated with ischemic stroke and was a strong predictor of poststroke death. (Stroke. 2012;43:658-663.)
S troke is one of the leading causes of death and long-term disability worldwide, 1 with conventional cardiovascular risk factors such as abnormal lipid metabolism, smoking, diabetes, and hypertension accounting for only 50 -60% of disease susceptibility. 2 Therefore, other risk factors predisposing to stroke and its clinical sequelae, and possibly leading to discovery of novel mechanisms, warrant further consideration. Because stroke is an age-related disease, premature biological (versus chronological) aging may contribute to its risk, and therefore molecular markers of aging, such as telomere length, may represent an important class of stroke risk factors.
Telomeres are the extreme ends of chromosomal DNA, composed of a variable number of tandem repeats of the sequence TTAGGG (in humans) that extend over several thousand base pairs. 3 The main function of telomeres is to cap and protect the ends of chromosomes to prevent loss of genetic information and avoid the activation of DNA-damage checkpoints that induce cell-cycle arrest (senescence) or apoptosis. 4, 5 In addition to genetic factors, 6 cellular environment is also known to affect telomere length. Most notably, oxidative stress and inflammation can shorten telomeres. [7] [8] [9] In vitro studies of vascular endothelial cells showed that telomere shortening induced senescence, demonstrating a possible mechanism by which telomere length may contribute to progressive endothelial dysfunction and atherosclerosis. 10 Because of their accessibility, leukocytes are useful in studying telomere length during in vivo aging. Moreover, previous studies have clearly established that age-dependent telomere shortening in circulating leukocytes is correlated with atherosclerosis and cardiovascular aging, 11, 12 indicating that leukocyte telomere length is a valuable biomarker for biological aging of the cardiovascular system.
In light of these observations, we hypothesized that leukocyte telomere length, as a marker of biological aging and possible indicator of cardiovascular dysfunction, may be associated with stroke. This hypothesis has been addressed previously; however, those studies reported largely negative, inconsistent, and inconclusive results with regard to stroke. [13] [14] [15] Specifically, prospective studies showed no association between leukocyte telomere length and stroke 13 or between leukocyte telomere length and death due to cardiovascular event including stroke. 14 A third prospective study in highrisk hypertensive patients showed that leukocyte telomere length was associated with a number of cross-sectional and prospective cardiovascular outcomes but not specifically with stroke. 15 Small sample sizes (Ͻ260 stroke patients for those studies) and ethnic variability probably contribute to the negative results and discrepancies. Moreover, Chinese subjects were underrepresented in previously studies, even though the very high incidence of stroke in the Chinese population, as compared with North Americans, suggests that Chinese may be an especially important and informative group for studying stroke risk factors. In the current study, we examined leukocyte telomere length in stroke patients and age-and sex-frequency-matched control subjects in a large case/control sample. We also assessed the potential of telomere length as a maker to predict stroke recurrence, coronary heart disease events, and death from all causes in a prospective cohort of Chinese stroke patients at 5 years of follow-up.
Methods

Study Populations
We performed a case-control study to determine the association between leukocyte telomere length and stroke. In brief, subjects (cases) who underwent strict neurological examination, computed tomography, or MRI were collected as previously described. 16 Ageand sex-matched healthy subjects (control subjects) were recruited from local communities. In addition, a second set of stoke patients from a prospective cohort study were included to assess whether shorter telomere length contributes to the risk of adverse outcomes after the first stroke. Follow-up visits of patients from the prospective cohort were performed by telephone or by household visit 5 years after the initial stroke. A detailed description of sample recruitment is provided in the online-only Supplemental Methods (http://stroke.ahajournals.org). There were no overlapping participants between the case/control and prospective cohort samples. All protocols and methods were approved by the ethics committees of the local participating hospitals. Written informed consent was obtained from all participants. Experiments were conducted according to the principles expressed in the Declaration of Helsinki.
Telomere Length Assay
Genomic DNA was isolated from whole blood collected in K 3 -EDTA tubes, using the QG-Mini80 workflow with a DB-S kit (FUJIFILM Corporation, Tokyo, Japan) as instructed. DNA was quantified and diluted to a final concentration of 10 ng/L. Telomere length ratio (T/S ratio) was measured from DNA, using a quantitative polymerase chain reaction (PCR)-based assay that compared the ratio of telomere sequence copy number (T) to single-copy gene copy number (human ␤-globin gene, located on chromosome 11; S) with the same calibrator sample. The primer sequences used for the telomeres and the human ␤-globin gene have been previously described. 17 All DNA samples were amplified using 10-L PCR, based on the 384-well ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). The thermal cycling profiles for both amplicons began with 95°C incubation for 10 minutes, followed by 30 cycles of 15 seconds at 95°C and 1 minute at 56°C for the telomere PCR or followed with 35 cycles of 15 seconds at 95°C and 1 minute at 58°C. The specificity of all amplifications was determined by melting curve analysis. A standard curve derived from serially diluted reference DNA (100.00 -1.56 ng; 2-fold dilution; 7 points) was run for both the telomere and human ␤-globin PCRs, with good linearity (R 2 Ͼ0.99 for both). For quality control purposes, a calibrator sample and 1 no-template control sample (all in triplicate) were additionally measured per run. The meanϮSD coefficients of variation were 1.3Ϯ0.9% for T/S ratio. All measurements were performed blinded with respect to clinical data.
Statistical Analysis
The distributions of quantitative variables were tested for normality by use of a 1-sample Kolmogorov-Smirnov test. Baseline quantitative variables, including age, body mass index (BMI), systolic blood pressure, and diastolic blood pressure, were compared with 1-way analysis of variance and the Dunnett test. The 2 test was used to compare qualitative variables. Because observed T/S ratio was not normally distributed, we performed the natural-log transformation before statistical analysis. For the case/control sample, the independent effect of teleomere length was tested using logistic regression while simultaneously adjusting for conventional risk factors, including sex, age, BMI, hypertension, diabetes, hyperlipidemia, and smoking status. Odds ratios were computed from regression parameters. In addition, we divided the distributions of the T/S ratio of telomere length among control subjects into quartiles; quartilespecific odds ratio of overall stroke and subtypes were estimated from different unconditional logistic regression models for both our main and subgroup analyses. For the prospective cohort, the predictive value of telomere length on outcomes during the 5-year follow-up period was analyzed by Cox proportional hazards models. All probability values were 2-sided. We conducted statistical analyses using SPSS version 13.0 software (SPSS Inc, Chicago, IL).
Results
The baseline characteristics of the case/control samples are shown in Table 1 . We observed that mean telomere length ratio was significantly different between stroke patients and control subjects (median, 1.25; interquartile range, 0.86 -1.86 versus 1.41; interquartile range, 1.01-2.20, respectively; PϽ0.001). The distribution of log T/S ratio as a function of chronological aging in cases and control subjects is shown in the Figure. Overall, telomere length ratio was significantly inversely correlated with age (regression coefficient ␤ϮSEϭϪ0.008Ϯ0.001; correlation coefficient (r)ϭϪ0.126, PϽ0.001). The telomere length ratio decreased steadily with age at a mean yearly rate of 0.007Ϯ0.002 (rϭϪ0.110, PϽ0.001) in stroke patients and 0.010Ϯ Ϯ0.002 (rϭϪ0.142, PϽ0.001) in control subjects, respectively.
In multiple unconditional logistic regression analysis, after adjustment for age, sex, BMI, hypertension, diabetes mellitus, hyperlipidemia and smoking status, decreased telomere length ratio was associated with overall stroke (odds ratio [OR], 1.46; 95% confidence interval [CI], 1.29 -1.66; PϽ0.001) and ischemic stroke (OR, 1.52; 95% CI, 1.31-1.67; PϽ0.001) except for hemorrhage stroke (OR, 1.22; 95% CI, 0.92-1.62; Pϭ0.172). Therefore, we focused on ischemic stroke and subtypes in follow-up analysis. Furthermore, when the study population was divided into quartiles, decreased telomere length ratio was also strongly and consistently associated with an increased risk of ischemic stroke (P for trend Ͻ0.001) ( Table 2 ). These associations were only slightly attenuated after further adjustment with conventional risk factors for stroke. The adjusted ORs for decreasing quartiles of telomere length ratio were 1.00, 1.37, 1.53, 2.12 for ischemic stroke; 1.00, 1.46, 1.48, 1.68 for thrombosis stroke; and 1.00, 1.20, 1.54, 3.14 for lacunar stroke, respectively (all P for trend Ͻ0.001) ( Table 2 ).
To explore whether age, sex, history of hypertension, diabetes mellitus, hyperlipidemia, smoking status, or BMI modified the observed associations, we conducted stratified analyses for case/control samples (online-only Supplemental Table I ). Significant associations were seen in most subgroups except for subjects who were overweight (BMI Ն25 kg/m 2 ) and Ͻ70 years of age. Associations were slightly stronger in men than women, in older compared with younger persons, and in normal-weight compared with overweight subjects. However, the probability values for interactions were not statistically significant, indicating that potential interaction or confounding by these factors is not meaningfully affecting our results. Similar results were found in ischemic stroke analysis (data not shown).
The prognostic value of telomere length stroke recurrence and death from all causes were next determined in the prospective cohort of stroke patients at 5-year follow-up. The baseline characteristics of study population categorized by telomere length quartiles are shown in Table 3 . Participants with longer telomere length were younger than those with shorter telomere length. There was a significant decrease in telomere length ratio with age in these patients (0.009Ϯ0.003 per year, rϭϪ0.102, PϽ0.001) (online-only Supplemental Figure I ), which was consistent with patients from the case/control sample. During the 5 years of follow-up, there were 137 stroke recurrence events, 71 coronary heart disease events, and 133 deaths. The number of stroke patients with adverse events separated by telomere length quartile and the corresponding adjusted hazard ratios are shown in Table 4 . The telomere length was not related to the stroke recurrence (P for trendϭ0.428) or coronary heart diseases events (P for trendϭ0.187), respectively. However, telomere length predicted death from all causes (P for trendϭ0.002). After adjustment with conventional risk factors, the hazard ratios comparing the extreme quartiles were 2.44 (95% CI, 1.39 -4.30) for death from all causes.
Discussion
In the present study, we found that leukocyte telomere length was significantly shorter in patients with stroke and that short baseline telomere length was significantly associated with increased risk for ischemic stroke and subtypes. These associations were independent of several well-known risk factors, including age, sex, BMI, hypertension, diabetes, hyperlipidemia, and smoking status. In addition, we further observed that telomere length is a strong and independent predictor for death from all causes.
The association of shorter telomeres with stroke patients may indicate the cumulative effect of other conventional risk factors leading to enhanced telomere loss over time. Epide- miological studies have shown that age-dependent shorter telomere length was associated with essential hypertension, 17 diabetes mellitus, 18 obesity, 19 smoking, 19 and coronary heart disease. 11 Alternatively, control subjects and patients with stroke may differ in their risk profiles, which could also explain the differences in telomere length. Other explanations also must be considered, including the genetic and environmental factors that affect telomere length. For example, physical activity and statin drug treatment may prevent yearly loss of telomere length. 20, 21 On average, the leukocyte telomere length in our stroke patients was comparable to that of control subjects chrono- logically 6 years older. Our findings lend support to the hypothesis that premature biological aging may contribute to the risk of stroke. However, the exact mechanism explaining the relationship between shorter telomere length and stroke cannot be determined from our study alone. Nevertheless, a plausible explanation for the shorter telomeres in leukocytes in patients with stroke is that it reflects increased leukocyte turnover as a consequence of the systemic chronic inflammation and oxidative stress that is now believed to occur in atherosclerosis and vascular diseases. 22 However, the question of whether telomere shortening is a causal factor in the pathogenesis of stroke, or whether both telomere shortening and stroke are caused by an unknown causal factor, warrants further investigation.
An important strength of this study was the highthroughput quantitative PCR-based method used to estimate mean telomere length, which has been previously shown to perform consistently with classic Southern blotting. 7, 23 Indeed, we observed a linear yearly loss of telomere length ratio of 0.007, which is highly consistent with findings from studies using alternative assays. 20, 24 This observation suggests that assessment of mean telomere length using the quantitative PCR-based method was reliable in our study.
Finally, there are several limitations in our study. First, although leukocytes provide an easily accessible source for DNA analysis (for both research and clinical purposes), the alternations in telomere length and the functions in cerebral vasculature remain to be established. There are limited data suggesting the general correlations between telomere lengths among different tissues, especially in cerebral vascular tissue. Second, telomere activity was not measured in the present study. Decreasing telomeres themselves but not the telomere length levels are the primary determinates of caused phenotypes. 25 Third, although our study shows convincingly that telomere shortening is associated with risk of ischemic stroke, no distinct cutoff can discriminate control subjects and stroke patients. Thus, the value of telomere length as an individual prognostic marker might not be clinically meaningful. Last, ischemic stroke classification was similar but not strictly in accordance with other commonly used criteria such as Trial of Org 10172 in Acute Stroke Treatment (TOAST) or the Oxford Community Stroke Project (OCSP) classification. However, given that our classification was similar to TOAST and that we diagnosed the subtypes of ischemic stroke by adequate image and physical examinations, we believe that there are no meaningful differences in the phenotype definition. In summary, our findings indicate that decreased telomere length was independently associated with elevated stroke risk in our Chinese subjects and that decreased telomere length was predictive of death from all causes within 5 years after first stroke. Future studies are needed to confirm these observations; however, results from this investigation have demonstrated that telomere length may serve as an informative predictor of stroke risk and that novel disease mechanisms related to telomere length may provide insight into the causes, prevention, and treatment of stroke.
SUPPLEMENTAL MATERIAL Study populations
Initially, a total of 1388 consecutive stroke patients were recruited to form the case sample as previously described. 1 Table II ). To minimize the confounding factors by age and sex, a total of 1309 control subjects were randomly selected from the pool of 5171 healthy residents of the local community participating in a community screening program during the same period with careful matching of age (±2 years) and sex frequency for each subtype of stroke respectively. These residents were randomly recruited from local community by a house-to-house recruitment protocol. All control subjects were free of neurological conditions and followed the same exclusion criteria as cases.
To assess whether shorter telomere length contributes to the risk of adverse outcomes after the first stroke, we introduced the prospective cohort that was comprised of 961 stroke patients as previously described elsewhere The diagnostic criteria for stroke were identical to those used in the first cohort.
There were no overlapping participants between these two samples. All of the enrolled patients were survivors of acute stroke events and followed up by a standard questionnaire and telephone contact by physician investigators to assess the recurrence of stroke and death. The patient or the care giver (typically a spouse or other family member) or both were asked whether the patient had experienced any type of stroke or new neurological symptoms (with detailed examples provided) or a decline in memory, language, or other cognitive function over the previous year. All reports of stroke events were confirmed by a local independent neurologist based on direct review of patient medical records and brain imaging. In those who had more than one recurrent stroke, only the first one was considered. Coronary heart disease (CHD) events were defined as one or more of the following medical records: (1) >50% stenosis in at least one of the major segments of coronary arteries assessed by coronary angiography; (2) World Health Organization criteria for elevated cardiac enzymes, typical ECG change, and clinical symptoms; or (3) documented history of coronary artery bypass graft or percutaneous coronary intervention. In cases of death, the medical records and the death certificates were reviewed, and a close relative or a caregiver was interviewed to screen for stroke recurrences prior to death. During the 5 years of follow-up 49 participants withdrew from the study due to emigration. Before data analysis, 54 subjects were excluded for the following reasons: insufficient DNA (N=13), poor DNA quality (N=21) or quality control of amplification data (N=20). Thus, 858 patients were included in final analysis. No significant difference was found in the characteristics between the original cohort and the sub-cohort after exclusion (see Table III ). All studies were approved by the ethics committees of the local participating hospitals. Written informed consent was obtained from all participants. Experiments were conducted according to the principles expressed in the Declaration of Helsinki.
Data collection and definition of risk factors
All stroke patients and control subjects received a physical examination with emphasis on the neurological system. Demographic data and other risk factors, including history of hypertension, diabetes, hyperlipidemia, smoking, and physical exercise, were collected by structured questionnaire. Hypertension was defined as systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg, or current treatment with an antihypertensive drug.
Diabetes was diagnosed by a fasting glucose level of >7.8 mmol/L and/or a glucose level of >11.1 mmol/L at 2 h after oral glucose challenge.
Hyperlipidemia was defined as total plasma cholesterol level of >5.72 mmol/L or plasma triglyceride >1.70 mmol/L. Smoking was defined as a history of smoking >2 pack-years and/or smoking within the preceding 1 year. Body mass index (kg/m2) was calculated from measurements of height and weight. 
